We have identi®ed 14-3-3 s (s) as a gene whose expression is lost in breast carcinomas, primarily by methylation-mediated silencing. In this report, we investigated the timing of loss of s gene expression during breast tumorigenesis in vivo. We analysed the methylation status of s in breast cancer precursor lesions using microdissection for selective tissue sampling. We found hypermethylation of s in 24 of 25 carcinomas (96%), 15 of 18 (83%) of ductal carcinoma in situ, and three of eight (38%) of atypical hyperplasias. None of the ®ve hyperplasias without atypia showed s-hypermethylation. Unexpectedly, patients with breast cancer showed s hypermethylation in adjacent histologically normal breast epithelium, while this was never observed in individuals without evidence of breast cancer. Also, samples of periductal stromal breast tissue were consistently hypermethylated, underscoring the importance of selective tissue sampling for accurate assessment of 14-3-3-s methylation in breast epithelium. These results suggest that hypermethylation of 14-3-3-s occurs at an early stage in the progression to invasive breast cancer, and may occur in apparently normal epithelium adjacent to breast cancer. These results provide evidence that loss of expression of s is an early event in neoplastic transformation. Oncogene (2001) 20, 3348 ± 3353.
Introduction
14-3-3-s (also called strati®n) was originally identi®ed as an epithelial-speci®c marker, HME1, which was downregulated in several breast cancer cell lines but not in cancer cell lines derived from other tissue types (Prasad et al., 1992) . The 14-3-3 proteins are a family of widely expressed regulatory molecules. Their ability to bind a variety of functionally diverse signaling proteins, including kinases, phosphatases, and transmembrane receptors, allows 14-3-3 proteins to play important roles in a wide range of regulatory processes, such as mitogenic signal transduction, cell cycle control, and apoptotic cell death (Chan et al., 1999; Fu et al., 2000) . In a recent paper, Dellambra et al., (2000) reported ecient and rapid immortalization of epithelial cells by introducing antisense s into primary keratinocytes, providing strong evidence for the importance of, and the early timing of loss of s in the transformation process.
We identi®ed 14-3-3-s as a gene whose expression is downregulated in breast cancer cells by SAGE analysis (Nacht et al., 1999) and veri®ed this ®nding by Northern blot analysis in primary breast carcinomas (Ferguson et al., 2000) . Investigating the molecular mechanism underlying the low expression of 14-3-3-s in breast cancers, we found that genetic alterations such as loss of heterozygosity (LOH) and intragenic mutations were not major contributing mechanisms (Ferguson et al., 2000) . Instead, sequencing of sodium bisul®te treated genomic DNA revealed hypermethylation of a discrete CpG-rich region in the 14-3-3-s gene which was associated with its transcriptional silencing in over 90% of invasive breast cancers (Ferguson et al., 2000) . We were able to show the functional importance of this hypermethylation, as treatment of s-nonexpressing breast cancer cell lines with the drug 5-aza-2'-deoxycytidine resulted in demethylation of the gene which coincided with the re-expression of speci®c 14-3-3-s mRNA (Ferguson et al., 2000) .
In this study, we have further investigated the status of 14-3-3-s methylation during the progression from normal breast epithelium to invasive breast cancer by analysing normal tissues, precursor lesions and carcinoma samples, often from the same patient. In order to avoid the contribution of contaminating nonepithelial cells in this study, all samples underwent selective sampling by manual or laser-capture microdissection, allowing independent analysis of the dierent components of the clinical breast tissue samples. Given the small amount of sample tissue available from precursor lesions and normal breast epithelium using this highly selective approach, the analysis of this CpG-island in the 14-3-3-s gene was performed by the sensitive methylation-speci®c PCR (MSP) technique (Herman Oncogene (2001) 20, 3348 ± 3353 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc et al., 1996) . Since transcriptional silencing of 14-3-3-s appears to be present in a very high proportion of invasive breast cancers, hypermethylation of s could serve as an excellent biomarker for neoplastic transformation in breast cells, as long as contaminating nontumor cells can be avoided.
Results

14.3.3-s in ductal carcinoma in situ (DCIS)
To begin our investigation of the timing of s methylation in breast cancer progression, we ®rst examined the methylation status of the s gene in microdissected cells from patients with breast carcinoma and DCIS, and patients with DCIS with no evidence of carcinoma. By methylation-speci®c PCR analysis of DNA from microdissected breast tissues, 24 of 25 samples of invasive breast cancer showed hypermethylation (see Figures 1 ± 3 and Table 1) . Surprisingly, 15/ 18 (83%) of ductal carcinoma in situ (DCIS) were also methylated. Five of the six cases which contained only DCIS were methylated. The concordance of s methylation between DCIS and concurrent invasive cancer was 10 out of 12 cases (83%) where tissue from both lesions was available (see Table 2 ). To ensure reproducibility between sections, duplicate samples from separate areas showing the same histology (10 invasive cancers and 10 DCIS) were obtained. The DCIS samples from which two independent areas were microdissected may or may not re¯ect independent lesions, since the 3D architecture could not be established. In each instance, both samples gave identical results.
14-3-3-s in atypical hyperplasias (AH) of the breast In our analysis of precancerous, hyperplastic breast tumors, 3/8 (38%) of atypical hyperplasias (AH) showed evidence of hypermethylation. None of the ®ve hyperplasias without atypia (NH) showed hypermethylation (see Figures 2a and 3 and Table 1 ).
The importance of selective microdissection of breast tissue for the analysis of s methylation was underscored by the ®nding that all 10 samples of periductal stroma showed hypermethylation, regardless of the methylation status of adjacent breast epithelium. Eight of 10 of the tissue blocks from which stromal cells were derived had no evidence of breast cancer, and adjacent epithelial breast tissue was completely unmethylated. Our previous results have shown that stromal cells do not express s (Ferguson et al., 2000) .
Finally, 22 tissue blocks contained sucient histologically normal ducts and acini to allow selective sampling of normal breast epithelium. Ten of 10 samples from patients without a diagnosis of breast cancer were unmethylated. Remarkably, nine of 11 patients with a diagnosis of breast cancer or DCIS showed hypermethylation of histologically normal breast epithelium (see Figures 2b and 3 and  Table 1 ). Unfortunately, no information regarding the exact topological relationship between the dissected tissue block and the primary tumor was available in these archival samples, but none of these blocks themselves contained cancer tissue, and had been harvested at the time of surgery as`adjacent normal control tissue'. The overall concordance for s hypermethylation between normal breast epithelium and adjacent benign or malignant tumor tissue was very high: in eight of the 10 cases (80%) where this parallel analysis could be performed, methylation status of 14-3-3-s agreed. No correlation of methylation levels of 14-3-3-s in breast epithelial samples with patient age were found for benign or malignant tissue (data not shown). The breast epithelium from normal breasts always contained unmethylated 14-3-3-s, irrespective of age. The result of the densitometric quantitation of the paired PCR products is expressed as per cent methylated fraction. A fraction of 410% is considered evidence of methylation of 14-3-3-s. Abbreviations are: nl, normal epithelium; CIS, ductal carcinoma in situ; Ca, invasive cancer. Samples from the same patient are indicated by long brackets. 231 and 435 are the breast cancer cell lines MDAMB231 and MDAMB435, respectively, which serve as control for fully unmethylated DNA and fully methylated DNA
14-3-3-s is hypermethylated in peripheral white blood cells
The presence of hypermethylated 14-3-3-s alleles in breast cancer in nearly all breast carcinomas raised a strong possibility that it could serve as a molecular marker for breast cancer. However, the presence of hypermethylated alleles in stroma surrounding breast epithelium, as shown above, precluded its use in the setting of ®ne needle or core biopsy of the breast in a facile and routine manner, since false positive results will be generated by the stromal cells contaminating the suspected tissue. Next, to determine whether the detection of 14-3-3-s in blood could prove to be of Figure 2 MSP analysis of genomic DNA from microdissected benign breast tissues. Paired samples of bisul®te-treated genomic DNA underwent PCR ampli®cation of 14-3-3-s with primers speci®c for either unmethylated (U) or methylated (M) DNA alleles. Abbreviations are: AH, atypical hyperplasia; ST, periductal stroma; nl, normal epithelium; HY, hyperplastic epithelium; Ca Patients, normal epithelium obtained from patients with breast cancer; NonCa Patients, normal epithelium obtained from patients without breast cancer. In (a), samples from the same patient are indicated by long brackets. 231 and 435 are the breast cancer cell lines MDAMB231 and MDAMB435, respectively, which serve as control for fully unmethylated DNA and fully methylated DNA Figure 3 Quantitative MSP analysis of 14-3-3-s from microdissected breast tissues. The results of the densitometric quantitation of the MSP analysis, expressed as per cent methylation fraction (see Materials and methods), are plotted for each microdissected breast tissue type. A fraction of 410% is considered evidence of methylation of 14-3-3-s. The means and standard deviations of each group are indicated by horizontal bars. The P values shown indicate signi®cant dierences between a tissue type and the normal epithelium, as determined by analysis of variance. Abbreviations are: AH, atypical hyperplasia; DCIS, ductal carcinoma in situ; Ca, invasive cancer; stroma, periductal stroma; Hy, hyperplastic epithelium; NL*, normal epithelium obtained from patients with breast cancer; Nl, normal epithelium obtained from patients without breast cancer signi®cance for diagnosis of disseminated disease in cases of metastatic breast cancer, we ®rst asked whether peripheral white blood cells (WBC's) from normal individuals contained methylated 14-3-3-s alleles, since it is known that peripheral WBC's do not show any expression of 14-3-3-s (Prasad et al., 1992) . Sodium bisul®te treated DNA from peripheral WBC's of nine individuals without known cancer was subjected to nucleotide sequencing. We found that the 27 CpGs in this region are hemi-or completely methylated in all nine samples (Figure 4 ).
Discussion
In this study, we sought to understand the importance of the methylation-mediated silencing of the 14-3-3-s gene which was previously detected in more than 95% of breast carcinomas (Ferguson et al., 2000) . In order to determine the stage of progression of the disease at which s methylation occurs, we studied dierent histologically recognized stages of breast cancer. One important ®nding of this investigation is that hypermethylation of the s locus is detectable with increasing frequency as the breast lesions progress from normal to atypical hyperplasia, to ductal carcinoma in situ, and ®nally to invasive carcinoma. In the absence of histological atypia, we were unable to detect any hypermethylation in breast epithelium of patients without breast cancer. Only 38% of atypical hyperplasias had evidence of hypermethylation. This increased to over 83% in DCIS samples, although 78% of these were associated with concurrent invasive breast cancer. Interestingly, two DCIS cases associated with invasive cancers showed no hypermethylation, suggesting either that the invasive cancer arose from a separate precursor, or that there is some variability in timing of the hypermethylation in the breast cancer progression.
The ®nding that almost all invasive breast cancer samples analysed by microdissection showed hypermethylation of 14-3-3 s con®rms our previous results in macroscopically processed invasive breast cancers containing 450% tumor cells, and suggests that contaminating stromal tissue was not the only source of hypermethylated s in those samples (Ferguson et al., 2000) . Since s is an epithelial cell-speci®c protein (Prasad et al., 1992) , our ®nding that it is methylated (and thereby silenced) in stromal tissue is not surprising. MSP and sequencing of sodium bisul®te-treated DNA showed that 14-3-3 s is also silenced by methylation in peripheral white blood cells (WBC's), another cell type that does not express s mRNA. In considering 14-3-3 s as a potential marker for breast cancer, these ®ndings in stroma and WBCs are very important. Unfortunately, although highly prevalent in breast cancers, the presence of methylated s in breast stroma and in WBCs preclude the utility of s as a breast cancer marker in clinical material. We are investigating the feasibility of a detection test that could be applied to breast epithelial cell populations selectively puri®ed by using immunobeads (Soria et al., 1999) .
The source of the unmethylated allele signal present in most MSP assays is not clear, and may be due to heterogeneous growth fractions in tissue samples, or it may suggest that a hemi-methylated state involving only one allele may be present in some tumors. As illustrated by our methylation controls, breast cancer cell lines are more homogenous in this respect, with the cell line MDAMB231 showing fully unmethylated s alleles and MDAMB435 showing fully methylated s alleles. This question will need to be addressed further by subcloning and sequencing of the individual alleles from appropriate tissue samples.
This study demonstrates that hypermethylation of 14-3-3-s occurs during the transition from late atypical hyperplastic lesions to DCIS to invasive cancer. These results suggest that hypermethylation-induced downregulation of s occurs at an early stage in the progression to invasive breast cancer, since hypermethylation of CpG islands is associated with transcriptional silencing (Baylin et al., 1998; Herman et al., 1996; Robertson and Jones, 2000) . Therefore, s hypermethylation may potentially be a useful marker in stratifying the risk of precancerous breast lesions. Although the site of the hypermethylated CpG island shortly after the transcriptional start site is less frequently seen in methylation-induced transcriptional silencing than the more common location in the upstream promoter region, it is not without precedent (Baylin et al., 1998; Robertson and Jones, 2000) . Furthermore, the island used for our MSP analysis was selected by sodium bisul®te sequencing of breast epithelial cell lines, and we have previously demonstrated the functional signi®cance of s methylation at this CpG island (Ferguson et al., 2000) .
One unexpected ®nding was that histologically benign breast epithelium was hypermethylated in patients with preinvasive and invasive breast cancer. Thus, it appears that s hypermethylation extends beyond the margins of the breast cancer tissue and involves morphologically intact breast tissue. This observation is reminiscent of the`®eld cancerization' seen in some cancers, for example, loss of heterozygosity of markers on chromosome 3p in breast cancer (Deng et al., 1996) , cytogenetic changes in the contralateral breast (Botti et al., 2000) , and p53 mutations in squamous cell cancers of the upper respiratory tract (Sidransky, 1997) .
In conclusion, hypermethylation of 14-3-3-s is a consistent alteration in invasive breast cancer, which is acquired in the late pre-invasive phase of tumor progression. When it occurs, it appears to involve breast epithelium beyond the margins of the primary tumor. While its prevalence makes it an attractive tumor marker, its utility is compromised by the presence of methylated alleles in the stroma and peripheral white blood cells. Great care must be taken to avoid contamination with non-epithelial cells if false positive assay results are to be avoided.
Materials and methods
Tissue samples
Primary breast tumor tissues were obtained immediately after surgical resection at the Johns Hopkins University or Duke University, and stored frozen at 7808C. Samples of non-malignant breast lesions were retrieved as paranembedded tissue blocks from surgical pathology archives at the same institutions. Microdissection was performed by using a laser capture microscope (Emmert-Buck et al., 1996) or by manually scraping the cells with a 25G needle under 406magni®cation (Umbricht et al., 1999) . Pairs of 8 mm cryosections or 4 mm paran sections were microdissected for DCIS and invasive cancers. Five paran sections were dissected for each precancerous and hyperplastic lesion. Genomic DNA was extracted by incubation of the microdissected cells at 458C612 h in 50 ml buer containing 10 mM TrisCl (pH 8.0), 1 mM EDTA, 0.1% Tween 20, and 0.5 mg/ml proteinase K. Unless large numbers of sections can be processed, microdissected tissue samples of small lesions typically do not yield sucient amounts of DNA for quantitation by optical density at 260 nm. We have estimated yields in the range of several hundred genome equivalents per sample using semiquantitative PCR of genomic DNA as described in (Umbricht et al., 1999) . Therefore, the entire DNA sample was submitted to MSP, and the presence of either methylated or unmethylated Figure 4 Nucleotide sequencing of 14-3-3-s-DNA following NaHSO3-treatment. The CpGs in the genomic 14-3-3-s sequence and the PCR primers used in the MSP analysis are shown. Open circles ± unmethylated; ®lled circles ± methylated; half-®lled circles ± hemi-methylated. MCF-10A and MDAMB231 are breast epithelial cell lines that express 14-3-3-s mRNA, and are unmethylated. Hs578T and MDAMB435 are methylated and show no detectable 14-3-3-s mRNA expression. Peripheral WBC #7151 ± 7159 are nine samples of genomic DNA extracted from WBC's of patients without known cancer product by MSP was used as load control to ensure adequate sampling.
Methylation-specific PCR (MSP)
Genomic DNA was treated with sodium bisul®te as described (Ferguson et al., 2000) , and was analysed by MSP using a primer set that covered CG dinucleotide numbers 3, 4, 8 and 9 (see Figure 1) . Primers speci®c for methylated DNA: 5'-TGGTAGTTTTTATGAAAGGCGTC-3' (sense) and 5'-CCTCTAACCGCCCACCACG-3' (antisense), and primers speci®c for unmethylated DNA: 5'-ATGGTAGTTTTTAT-GAAAGGTGTT-3' (sense) and 5'-CCCTCTAACCACC-CACCACA-3' (antisense) yielded a 105 bp and 107 bp PCR product, respectively. The PCR conditions were as follows: 1 cycle of 958C for 5 min; 31 cycles of 958C for 45 s, 568C for 30 s and 728C for 30 s; and 1 cycle of 728C for 4 min. The PCR samples were resolved by electrophoresis in a 2% agarose gel and stained with ethidium bromide.
Semiquantitative assessment of MSP
The intensity of the paired methylation-speci®c and nonmethylation-speci®c PCR product bands were quanti®ed densitometrically using the IPLab-Gel software package (Signal Analytics Corp., Vienna, VA, USA) on a Macintosh microcomputer. Two breast cancer cell lines with known 14-3-3-s methylation state were routinely run along with clinical samples. Based on sodium bisul®te sequencing, MDAMB231 has fully unmethylated s alleles and MDAMB435 has fully methylated s alleles (Ferguson et al., 2000) . Using these two cell lines, serial dilutions (100 ng to 1 ng of DNA), and mixing experiments (1 : 10 to 1 : 10 000 mixtures) with varying PCR cycle numbers were performed to establish the linear range of the assay. Ten ng amounts of DNA could be reliably detected by MSP using the conditions described here, in mixtures of up to 1 : 500. Under the PCR conditions chosen, both sets of primers produced equivalent band intensities speci®c for the appropriate cell line (see Figure   1 ). Experimental results were expressed as per cent methylated band signal or per cent methylation fraction, which was calculated as follows: I{M} * 100 / (I{U}+I{M}), where I{M} is intensity of methylated band and I{U} is intensity of unmethylated band. A threshold level of 10% methylated band signal was chosen as evidence of presence or absence of hypermethylation of the 14-3-3-s CpG island in the tissue samples. This was based upon our highly reproducible ®ndings of a 5 ± 10% methylation fraction in MDAMB231 and a 90 ± 95% methylation fraction in MDAMB231 by the densitometric assay. Since the paired PCR reactions served as reciprocal load controls, the presence of signal in at least one reaction was required to indicate an adequate tissue sample.
Sequencing of 14-3-3-s in sodium bisulfite modified DNA DNA from peripheral WBCs from nine normal individuals was treated with sodium bisul®te overnight as previously described (Ferguson et al., 2000) . Brie¯y, the DNA was puri®ed and the CpG island in the ®rst exon ampli®ed by PCR using the following primers: 5'-GAGAGAGTTAGTTT-GATTTAGAAG-3' (sense primer with start at nt 8641) and 5'-CTTACTAATATCCATAACCTCC-3' (antisense primer with start at nt 9114) which generated a 474 bp PCR product. The product was puri®ed using a Qiagen PCR puri®cation kit (Qiagen Corp) and sequenced using the sense primer with an ABI automated¯uorescent sequencer according to the manufacturer's instructions.
